Drug Database
IN

interferon beta-1a (ReciGen)

✓ Approved

Cinnagen Co · IFNAR2 · 重组蛋白

什么是 interferon beta-1a?

interferon beta-1a 是一种重组蛋白,由Cinnagen Co研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名ReciGen
公司Cinnagen Co
药物类别重组蛋白
分子靶点IFNAR2
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved

作用机制

分子靶点

interferon beta-1a 作用于 1 个分子靶点:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

interferon beta-1a 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersRelapsing-remitting multiple sclerosis✓ Approved
Nervous system disordersProgressive relapsing multiple sclerosis✓ Approved

相关研究文献

PubMedFrontiers in immunology2026-11-17

HERC5-mediated co-translational ISGylation in innate immunity: molecular mechanisms, context-dependent regulation, and therapeutic potential.

Huang Xiaomei X, Huang Fengdie F, Luo Dongrong D, Li Shiying S et al.

HERC5 is the predominant E3 ligase for interferon-stimulated gene 15 (ISG15) in human cells and is now considered a central component of interferon-driven innate immune regulation. Unlike conventional E3 ligases that primarily modify mature proteins, HERC5 has been reported to mediate co-translational ISGylation by associating with ribosomes and modifying nascent polypeptides during protein synthesis, providing a mechanistic link between interferon activation, protein modification, and rapid cellular adaptation during immune responses. Accumulating evidence suggests that HERC5-mediated ISGylation contributes to multiple aspects of antiviral defense, amplification of interferon signaling, pathogen-host interactions, and immune homeostasis. Beyond its canonical antiviral functions, emerging studies reveal that dysregulated HERC5 activity contributes to immune-associated pathological processes, including inflammatory disorders, tumor-associated immune regulation, and stress-induced cellular adaptation. However, the molecular principles that determine how HERC5 generates distinct biological outcomes across cellular and pathological contexts remain incompletely understood. In this Review, we critically synthesize selected mechanistic, experimental, and clinical evidence on HERC5-mediated co-translational ISGylation and propose a context-dependent regulatory framework in which HERC5 functions as an interferon-responsive ISGylation hub. We discuss three interconnected regulatory axes: the interferon-ISGylation axis, which governs antiviral immunity and innate immune signaling amplification; the stress adaptation and homeostasis axis, which links HERC5 activity to cellular adaptation and proteome regulation during immune responses; and the disease-associated rewiring axis, which describes how altered HERC5-mediated ISGylation contributes to pathological immune signaling. These axes provide a conceptual framework for comparing experimentally established mechanisms with disease-associated observations rather than implying a universal causal pathway. Furthermore, we highlight the emerging translational potential of HERC5 as a biomarker and therapeutic target, including nanobody-based ISGylation-targeting chimeras (NITACs) as a programmable strategy for modulating ISGylation-dependent immune pathways. Collectively, this Review highlights HERC5-mediated co-translational ISGylation as an emerging regulatory interface linking innate immunity, proteostasis, and immune-associated diseases.

PMID 43041922
阅读全文 →
PubMedFrontiers in immunology2026-11-17

BAP1 as a novel regulator of type I interferon signaling through transcriptional control of key response machinery components.

Mortazavi Yasaman Y, Zhang Hanyue H, Herrera Robert R, Cook Ryan R et al.

Type I interferon (IFN-I) signaling is critical for dual immunity, defending against microbial infections and augmenting anti-tumor immune responses. Research in the past few decades have identified the key machinery components and over 300 interferon-stimulated genes (ISGs) that comprise the IFN-I signaling network. While cascade amplification mechanisms ensure robust pathway activation, appropriate expression of signaling components is essential for maintaining pathway sensitivity, enabling efficient signal amplification, and providing adequate host responses. Here, we identified BRCA1-associated protein-1 (BAP1) as a positive regulator of the IFN-I signaling pathway through a genome-wide CRISPR/Cas9 screen in murine macrophage Raw264.7 cells stimulated with cGAMP. We confirmed both the enzymatic activity and nuclear localization of BAP1 were essential for this regulation. Our findings reveal that BAP1 regulates a broad transcriptional program essential for IFN-I responses, including IFNAR1 and IFNAR2. BAP1 deficient cells failed to mount an effective IFN-I response, showing markedly reduced ISGs and resulting in uncontrolled viral replication. These findings together highlight an essential role of BAP1 in controlling IFN-I signaling and antiviral responses.

PMID 43041536
阅读全文 →
PubMedJournal of virology2026-11-17

A chicken interferon-stimulated gene screen reveals limited genes restricting influenza virus replication.

Barkhymer Alison J AJ, Becker Jordan T JT, Shepherd Frances K FK, Mickelson Clayton K CK et al.

Avian influenza A virus (IAV) is a major global health threat. Not only does it cause significant economic losses to the agricultural industry, but it also presents a risk of spillover into the human population. However, several obstacles must be overcome for a successful cross-species transmission event to occur. One of these obstacles is the innate immunity of the host. While the innate immune response to IAV in humans has been well-studied, the innate immune response to IAV in birds is not as well understood. Here, we explore the interferon-induced immune response by identifying interferon-stimulated genes (ISGs) in chicken, quail, and duck cells, and find that they are largely species-specific. Using this data, we performed a CRISPR knockout ISG screen against two strains of IAV, the mouse-adapted PR8, and the low pathogenicity avian IAV isolate WF10. We find that for PR8, IFITM3 is the dominant restrictor of viral replication with several additional hits with modest effects, consistent with previous work in mammals. For avian WF10, IFITM3 was also a hit; however, there were two additional hits absent for PR8, the HSP70 co-chaperone protein BAG5 and the deubiquitinase OTUD4. Overall, these findings confirm the divergence of interferon-mediated immunity between species and establish a screening system that can be used to identify ISGs important for viral restriction in avian species.IMPORTANCEWild birds, especially waterfowl and shorebirds, are the primary natural reservoir for influenza A viruses. These birds can transmit IAV to domestic poultry, where the spillover risk to humans increases. Chickens are the most common species of domestic poultry worldwide and frequently infected with avian influenza viruses. Despite this, relatively little is known about how their immune system responds to influenza infection. This lack of knowledge creates a barrier to finding ways of preventing or mitigating IAV infection in chicken flocks. In this study, we characterized the interferon-induced immune response to IAV in chickens and found that only a small subset of ISGs were responsible for restricting IAV in chicken cells.

PMID 43042969
阅读全文 →
PubMedACS medicinal chemistry letters2026-11-17

Synthesis and Evaluation of Mevalonate Diphosphate Analogs as Butyrophilin 3A3 Ligands.

Singh Umed U, Hsiao Chia-Hung Christine CC, Wiemer David F DF, Wiemer Andrew J AJ

Butyrophilin 3A3 (BTN3A3) senses mevalonate-derived phosphoantigens (pAgs), but its ligand chemistry remains unexplored. We synthesized phosphonate analogs of mevalonate diphosphate (MPP) and evaluated their stimulation of γ9δ2 T cells. Several compounds induced interferon γ production from human effector γ9δ2 T cells, although none potently stimulated naïve-γ9δ2 T cell proliferation. Compound 17 was the most active pAg; it outperformed MPP and preferentially acted in BTN3A3-expressing cells. Compound 17 resisted the lovastatin-mediated pathway blockade and, importantly, synergized with POM2-C-HMBP, a BTN3A1 agonist. These findings identify 17 as a BTN3A3-biased pAg and support chemically tuning mevalonate-derived scaffolds to modulate γ9δ2 T cell responses.

PMID 43041857
阅读全文 →
PubMedFrontiers in immunology2026-11-17

Single-cell analysis reveals transcriptomic patterns in active macrophage activation syndrome and therapeutic potential of albumin-fused interleukin-10 in a mouse model.

Fujii Wataru W, Sofue Hideaki H, Yuba Eiji E, Ishihara Jun J et al.

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening hyperinflammatory conditions. We aimed to characterize immune cell transcriptomic patterns in human MAS and investigate the therapeutic potential of albumin-fused IL-10 protein (SA-IL-10) in a MAS mouse model. We performed single-cell RNA sequencing (scRNA-seq) on bone marrow and peripheral blood samples from patients with newly developed MAS caused by diverse etiologies. We generated paired Seq-Well single-cell transcriptomes from bone marrow and blood of patients with active HLH/MAS. In the absence of a contemporaneous control cohort, technology-matched public Seq-Well marrow and same-laboratory control blood were projected onto the frozen patient atlases as lineage context, not as a case-control comparison. We also evaluated the effect of SA-IL-10 in a CpG-DNA-induced mouse model of MAS. Human scRNA-seq identified diverse immune cell populations, including dendritic cells, macrophages, and monocyte subsets. Canonical lineages in the public data were transferred to the expected patient states. Monocyte 1 and macrophage populations expressed transcripts encoding IL-10 receptor subunits and associated signaling molecules, although these findings reflect RNA abundance and do not establish functional responsiveness. Donor-level phagocytosis and interferon-γ programs showed no significant differences after multiple-testing correction. In the mouse model, SA-IL-10 treatment significantly improved anemia, leukocytopenia, splenomegaly, and liver dysfunction and was associated with reduced circulating interferon-γ levels and bone marrow macrophage abundance. Human scRNA-seq provides transcriptomic patterns in active HLH/MAS. The therapeutic effects observed in the mouse model support further investigation of SA-IL-10 as a potential treatment for MAS.

PMID 43041366
阅读全文 →
PubMedAmerican heart journal plus : cardiology research and practice2026-11-17

In-hospital outcomes associated with renin-angiotensin system inhibitors, Beta-blockers, and mineralocorticoid receptor antagonists in acute decompensated heart failure: Analysis by chronic kidney disease status and heart failure subtypes.

Yang Shang-Feng SF, Liu I-Fan IF, Tsao Tien-Ping TP, Tsai Shin-Hung SH

Associations between early inpatient neurohormonal antagonist prescriptions and outcomes in acute decompensated heart failure (ADHF) remain incompletely characterized across kidney function and heart failure subtypes. In 2208 ADHF admissions, adjusted logistic regression assessed ACE inhibitor/angiotensin receptor blocker (ACEi/ARB), beta-blocker, and mineralocorticoid receptor antagonist (MRA) prescriptions during the first seven days in relation to worsening renal function (WRF), mortality, and their composite, stratified by CKD and ejection fraction. Sensitivity analyses examined a day-7 landmark cohort and pre-admission medication history. ACEi/ARB prescriptions were associated with lower adjusted odds of WRF (adjusted odds ratio [aOR] 0.70, 95% confidence interval [CI] 0.57-0.87) and in-hospital mortality (aOR 0.54, 95% CI 0.34-0.86); MRA showed similar associations, whereas beta-blockers showed none. Significant estimates were observed in HFrEF (WRF aOR 0.61 for ACEi/ARB and 0.53 for MRA) but generally not in LVEF >40%, and CKD status did not modify these associations (all P for interaction >0.05). In a day-7 landmark analysis excluding early WRF, first-onset WRF associations were attenuated and no longer significant overall but persisted in HFrEF. New ACEi/ARB and MRA users had lower WRF odds than never users but did not differ from continuing users; continuing beta-blocker users had higher WRF odds than new users. In this ADHF cohort, ACEi/ARB and MRA use was associated with lower odds of WRF, but associations weakened after accounting for onset timing and remained significant only in HFrEF. These observational findings do not establish treatment benefit.

PMID 43041807
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多interferon beta-1a